Genital Herpes Market Report 2026

The genital herpes market size has grown strongly in recent years. It will grow from $2.34 billion in 2025 to $2.49 billion in 2026 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to high prevalence of hsv infections, availability of antiviral drugs, public health screening initiatives, sexual health education programs, clinical diagnosis protocols.

The genital herpes market size is expected to see strong growth in the next few years. It will grow to $3.15 billion in 2030 at a compound annual growth rate (CAGR) of 6%. The growth in the forecast period can be attributed to development of preventive vaccines, expansion of rapid diagnostics, improved patient adherence therapies, digital sexual health services, increased healthcare access. Major trends in the forecast period include increasing use of antiviral suppressive therapy, rising awareness and early diagnosis of stis, growing demand for point-of-care diagnostic tests, expansion of preventive sexual health programs, increased focus on long-term symptom management.

The increasing emphasis on sexual health is expected to drive the growth of the genital herpes market in the coming years. This heightened focus on sexual health arises from growing awareness of its importance to overall well-being and quality of life. Sexual health services related to genital herpes mainly include diagnosis, treatment, counseling, and long-term management to help individuals control outbreaks, reduce transmission risk, and address the emotional and relationship challenges associated with the condition. For example, in September 2025, the Centers for Disease Control and Prevention, a US-based public health agency, reported that more than 2.2 million cases of chlamydia, gonorrhea, and syphilis were recorded in 2024. Consequently, the growing focus on sexual health is contributing to the expansion of the genital herpes market.

Key players in the genital herpes market are increasingly engaging in strategic partnerships to enhance technological capabilities and broaden their market reach. Strategic partnerships involve collaboration between organizations that pool resources, expertise, and capabilities to achieve common goals. For instance, in December 2024, Changchun Baike Biotechnology, a China-based biotechnology firm, and Zhuhai Livanda Biotechnology, a China-based biopharmaceutical company, jointly received authorization from China’s National Medical Products Administration to begin clinical trials of LVRNA101, a multi-component mRNA vaccine targeting Herpes Simplex Virus Type 2 (HSV-2), which causes genital herpes. The vaccine is designed to stimulate both humoral and cellular immune responses through advanced mRNA technology.

In October 2023, Gilead Sciences, a US-based biopharmaceutical company known for antiviral therapies for HIV, hepatitis, and other viral infections, entered into a strategic collaboration with Assembly Biosciences to develop next-generation treatments for serious viral diseases, including genital herpes (HSV-2). Through this collaboration, the companies aim to combine their expertise to speed up the development and commercialization of innovative antiviral therapies, strengthening therapeutic offerings and expanding their presence in the viral disease market. Assembly Biosciences is a US-based biopharmaceutical company focused on creating novel treatments for viral infectious diseases, including long-acting helicase-primase inhibitors for recurrent genital herpes.

Major companies operating in the genital herpes market are Merck & Co Inc, Abbott Laboratories, GlaxoSmithKline plc, Viatris Inc, Teva Pharmaceuticals Inc, Sandoz Inc, Valeant Pharmaceuticals International Inc, Sun Pharmaceutical Industries Ltd, Dr Reddy’s Laboratories Ltd, Apotex Inc, Zydus Group, Genocea Biosciences Inc, Glenmark Pharmaceuticals Inc, Maruho Co Ltd, Eurocine Vaccines AB, Vical Incorporated, Gilead Sciences Inc, Johnson & Johnson Inc, AstraZeneca plc, Moderna Inc, Assembly Biosciences Inc.

North America was the largest region in the genital herpes market in 2025. The regions covered in the genital herpes market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the genital herpes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the genital herpes market by increasing costs of imported antiviral medications, diagnostic kits, and laboratory reagents. Hospitals and retail pharmacies in developed regions are most affected due to reliance on imported drugs. These tariffs increase treatment costs by raising prices of antiviral therapies and confirmatory diagnostics, affecting long-term disease management and patient adherence. However, they promote domestic pharmaceutical production, strengthening local manufacturing of antiviral drugs and reducing dependency on imported medications.

The genital herpes market research report is one of a series of new reports that provides genital herpes market statistics, including genital herpes industry global market size, regional shares, competitors with a genital herpes market share, detailed genital herpes market segments, market trends and opportunities, and any further data you may need to thrive in the genital herpes industry. This genital herpes market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Genital herpes is a sexually transmitted infection (STI) mainly caused by the herpes simplex virus type 2 (HSV-2) and, less frequently, by herpes simplex virus type 1 (HSV-1). It commonly presents as blisters or sores in the genital area, buttocks, or anal region. The infection is spread through sexual contact with an infected individual and can be managed using antiviral medications to help control symptoms and reduce the risk of transmission to sexual partners.

The primary types of genital herpes include diagnosis and treatment. Diagnosis involves the techniques and procedures used to detect the presence of genital herpes in patients, such as physical examinations, laboratory testing, and reviews of medical history to confirm infection. The routes of administration include oral, injectable, and topical methods, while the distribution channels consist of hospital pharmacies, retail pharmacies, and other outlets.

The genital herpes market consists of revenues earned by entities by providing services such as diagnostic testing, patient education, counseling, and management of symptoms and outbreaks. The market value includes the value of related goods sold by the service provider or included within the service offering. The genital herpes market also includes sales of antiviral medications, topical treatments, diagnostic test kits, and preventive products like vaccines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.